Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 2
---
 that it no longer qualified as a "foreign private issuer", as defined in Rule 405 under the Securities Act of 1933, as amended (the "Securities Act"), and, effective as of January 1, 2025, was subject to registration requirements applicable to a United States domestic registrant.

This Post-Effective Amendment No. 1 to the Previous Registration Statement is being filed to (i) convert the Previous Registration Statement into a Registration Statement on Form S-1 and (ii) update the prospectus relating to the securities that were registered under the Previous Registration Statement, including with the information contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 28, 2025.

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the Registration Statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>Subject to Completion. Dated April 4, 2025</div>

Preliminary Prospectus

<div align='center'>1,115,500 Common Shares Issuable upon the Exercise of Warrants

Medicus Pharma Ltd.</div>

This prospectus relates to up to 1,115,500 common shares of Medicus Pharma Ltd. (the "Company"), no par value (the "common shares"), issuable from time to time upon the exercise of 1,115,500 outstanding public warrants to purchase common shares, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), which were issued as a component of the units sold by the Company in its U.S. initial public offering.

Our common shares and Public Warrants are listed on The Nasdaq Capital Market (the "Nasdaq"), under the symbols "MDCX" and "MDCXW," respectively.

The closing price of our common shares and Public Warrants on the Nasdaq on April 3, 2025 were $3.75 and $0.60, respectively.

We are an "emerging growth company" and a "smaller reporting company" under applicable U.S. Securities and Exchange Commission rules and will be eligible for reduced public company disclosure requirements. See"Prospect